REFERENCES
1. Marc TG, Gurney JG, Smith MA, Olshan AF. Sympathetic nervous system tumors. In: Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, editors. Cancer incidence and survival among children and adolescents: United States SEER program 1975-1995. USA NCI Pub; 1999. pp. 65-72.
2. Gurney JG, Smith MA, Ross JA. Cancer among infants. In: Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, editors. Cancer incidence and survival among children and adolescents: United States SEER program 1975-1995. USA NCI Pub; 1999. pp. 149-56.
3. Morgenstern DA, Baruchel S, Irwin MS. Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy. J Pediatr Hematol Oncol 2013;35:337-47.
4. Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 2010;28:2625-34.
5. American Cancer Society. Cancer facts & figures 2019. Atlanta: American Cancer Society. 2019;1:1-76.
6. Santana VM, Furman WL, McGregor LM, Billups CA. Disease control intervals in high-risk neuroblastoma. Cancer 2008;112:2796-801.
7. Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, et al. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer 2011;56:578-83.
8. Lau L, Tai D, Weitzman S, Grant R, Baruchel S, et al. Factors influencing survival in children with recurrent neuroblastoma. J Pediatr Hematol Oncol 2004;26:227-32.
9. Berthold F, Hero B, Breu H, Christiansen H, Erttmann R, et al. The recurrence patterns of stages I, II and III neuroblastoma: experience with 77 relapsing patients. Ann Oncol 1996;7:183-7.
10. Molenaar JJ, Ebus ME, Koster J, van Sluis P, van Noesel CJ, et al. Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Res 2008;68:2599-609.
11. Moll UM, LaQuaglia M, Bénard J, Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci U S A 1995;92:4407-11.
12. Barbieri E, De Preter K, Capasso M, Chen Z, Hsu DM, et al. Histone chaperone CHAF1A inhibits differentiation and promotes aggressive neuroblastoma. Cancer Res 2014;74:765-74.
13. Bhaskara VK, Mohanam I, Rao JS, Mohanam S. Intermittent hypoxia regulates stem-like characteristics and differentiation of neuroblastoma cells. PLoS One 2012;7:e30905.
14. Schleiermacher G, Janoueix-Lerosey I, Delattre O. Recent insights into the biology of neuroblastoma. Int J Cancer 2014;135:2249-61.
15. Abdullah LN, Chow EK. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med 2013;2:3.
16. Alisi A, Cho WC, Locatelli F, Fruci D. Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastoma. Int J Mol Sci 2013;14:24706-25.
18. Ross RA, Biedler JL, Spengler BA. A role for distinct cell types in determining malignancy in human neuroblastoma cell lines and tumors. Cancer Lett 2003;197:35-9.
19. Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992;255:1707-10.
20. Linabery AM, Ross JA. Trends in childhood cancer incidence in the US (1992-2004). Cancer 2008;112:416-32.
21. Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011;103:714-36.
22. de Weille J. On the genesis of neuroblastoma and glioma. Int J Brain Sci 2014;2014:14.
23. Kerosuo L, Bronner-Fraser M. What is bad in cancer is good in the embryo: importance of EMT in neural crest development. Semin Cell Dev Biol 2012;23:320-32.
24. Albino D, Brizzolara A, Moretti S, Falugi C, Mirisola V, et al. Gene expression profiling identifies eleven DNA repair genes down-regulated during mouse neural crest cell migration. Int J Dev Biol 2011;55:65-72.
25. Crane JF, Trainor PA. Neural crest stem and progenitor cells. Annu Rev Cell Dev Biol 2006;22:267-86.
26. Mohlin SA, Wigerup C, Påhlman S. Neuroblastoma aggressiveness in relation to sympathetic neuronal differentiation stage. Seminars Cancer Biol 2011;21:276-82.
27. Craft AW, Parker L. Poor prognosis neuroblastoma: is screening the answer? Br J Cancer Suppl 1992;18:S96-101.
28. Sawada T. Past and future of neuroblastoma screening in Japan. Am J Pediatr Hematol Oncol 1992;14:320-6.
29. Jiang M, Stanke J, Lahti JM. The connections between neural crest development and neuroblastoma. Curr Top Dev Biol 2011;94:77-127.
30. Walton JD, Kattan DR, Thomas SK, Spengler BA, Guo HF, et al. Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia 2004;6:838-45.
31. Longo L, Panza E, Schena F, Seri M, Devoto M, et al. Genetic predisposition to familial neuroblastoma: identification of two novel genomic regions at 2p and 12p. Hum Hered 2007;63:205-11.
32. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930-5.
33. Melotte V, Qu X, Ongenaert M, Van Criekinge W, de Bruïne AP, et al. The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications. FASEB J 2010;24:4153-66.
34. Bosse KR, Diskin SJ, Cole KA, Wood AC, Schnepp RW, et al. Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity. Cancer Res 2012;72:2068-78.
35. Oldridge DA, Wood AC, Weichert-Leahey N, Crimmins I, Sussman R, et al. Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. Nature 2015;528:418-21.
36. Schnepp RW, Khurana P, Attiyeh EF, Raman P, Chodosh SE, et al. A LIN28B-RAN-AURKA signaling network promotes neuroblastoma tumorigenesis. Cancer cell 2015;28:599-609.
37. Schramm A, Koster J, Assenov Y, Althoff K, Peifer M, et al. Mutational dynamics between primary and relapse neuroblastomas. Na Genet 2015;47:872-7.
38. Gaisie G, Oh KS, Young LW. Coexistent neuroblastoma and Hirschsprung’s disease - another manifestation of the neurocristopathy? Pediatr Radiol 1979;8:161-3.
39. Roshkow JE, Haller JO, Berdon WE, Sane SM. Hirschsprung’s disease, Ondine’s curse, and neuroblastoma-manifestations of neurocristopathy. Pediatr Radiol 1988;19:45-9.
40. Quackenbush KE, Luna-Fineman S, Magee JF, Gundogan M, Golobi M, et al. Neuroblastoma involvement of the falx cerebri. Pediatr Blood Cancer 2009;53:1337-9.
41. Emery LG, Shields M, Shah NR, Garbes A. Neuroblastoma associated with beckwith-wiedemann syndrome. Cancer 1983;52:176-9.
42. Kenny FM, Stavrides A, Voorhess ML, Klein R. Cushing’s syndrome associated with an adrenal neuroblastoma: a case in an infant with clinical, pathological, and adrenal cortical and medullary hormone excretion studies. Am J Dis Child 1967;113:611-5.
43. Arnesen MA, Scheithauer BW, Freeman S. Cushing’s syndrome secondary to olfactory neuroblastoma. Ultrastruct Pathol 1994;18:61-8.
44. Kinney H, Faix R, Brazy J. The fetal alcohol syndrome and neuroblastoma. Pediatrics 1980;66:130-2.
45. Yang Q, Olshan AF, Bondy ML, Shah NR, Pollock BH, et al. Parental smoking and alcohol consumption and risk of neuroblastoma. Cancer Epidemiol Biomarkers Prev 2000;9:967-72.
46. Schüz J, Kaletsch U, Meinert R, Kaatsch P, Spix C, et al. Risk factors for neuroblastoma at different stages of disease. Results from a population-based case-control study in Germany. J Clin Epidemiol 2001;54:702-9.
47. Al-Shammri S, Guberman A, Hsu E. Neuroblastoma and fetal exposure to phenytoin in a child without dysmorphic features. Can J Neurol Sci 1992;19:243-5.
49. Dragu DL, Necula LG, Bleotu C, Diaconu CC, Chivu-Economescu M. Therapies targeting cancer stem cells: Current trends and future challenges. World J Stem Cells 2015;7:1185-201.
50. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;130:194-5.
51. Yamashita T, Wang XW. Cancer stem cells in the development of liver cancer. J Clin Invest 2013;123:1911-8.
52. Wang Y, He L, Du Y, Zhu P, Huang G, et al. The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling. Cell Stem Cell 2015;16:413-25.
53. Alamgeer M, Peacock CD, Matsui W, Ganju V, Watkins DN. Cancer stem cells in lung cancer: evidence and controversies. Respirology 2013;18:757-64.
54. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8.
55. Han J, Fujisawa T, Husain SR, Puri RK. Identification and characterization of cancer stem cells in human head and neck squamous cell carcinoma. BMC cancer 2014;14:173.
56. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007;104:10158-63.
57. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-5.
58. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401.
59. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7.
60. Hansford LM, McKee AE, Zhang L, George RE, Gerstle JT, et al. Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res 2007;67:11234-43.
61. Mahller YY, Williams JP, Baird WH, Mitton B, Grossheim J, et al. Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One 2009;4:e4235.
62. Peiris-Pages M, Martinez-Outschoorn UE, Pestell RG, Sotgia F, Lisanti MP. Cancer stem cell metabolism. Breast Cancer Res 2016;18:55.
63. Prieto-Vila M, Takahashi RU, Usuba W, Kohama I, Ochiya T. Drug resistance driven by cancer stem cells and their niche. Int J Mol Sci 2017;18:E2574.
65. Dean M. Cancer stem cells: Implications for cancer causation and therapy resistance. Discov Med 2005;5:278-82.
66. Khalil MA, Hrabeta J, Cipro S, Stiborova M, Vicha A, et al. Neuroblastoma stem cells - mechanisms of chemoresistance and histone deacetylase inhibitors. Neoplasma 2012;59:737-46.
67. Naiditch JA, Jie C, Lautz TB, Yu S, Clark S, et al. Mesenchymal change and drug resistance in neuroblastoma. J Surg Res 2015;193:279-88.
68. Biedler JL, Helson L, Spengler BA. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 1973;33:2643-52.
69. Ross RA, Spengler BA, Domenech C, Porubcin M, Rettig WJ, et al. Human neuroblastoma I-type cells are malignant neural crest stem cells. Cell Growth Differ 1995;6:449-56.
70. Walton JD, Kattan DR, Thomas SK, Spengler BA, Guo HF, et al. Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia 2004;6:838-45.
71. Ross RA, Walton JD, Han D, Guo HF, Cheung NK. A distinct gene expression signature characterizes human neuroblastoma cancer stem cells. Stem Cell Res 2015;15:419-26.
72. Buhagiar A, Ayers D. Chemoresistance, cancer stem cells, and miRNA influences: the case for neuroblastoma. Anal Cell Pathol (Amst) 2015;2015:150634.
73. Oh L, Hafsi H, Hainaut P, Ariffin H. P53, stem cell biology and childhood blastomas. Curr Opin Oncol 2019;31:84-91.
74. Friedman GK, Gillespie GY. Cancer stem cells and pediatric solid tumors. Cancers (Basel) 2011;3:298-318.
75. Garner EF, Beierle EA. Cancer stem cells and their interaction with the tumor microenvironment in neuroblastoma. Cancers (Basel) 2015;8:e5.
77. Phi LTH, Sari IN, Yang YG, Lee SH, Jun N, et al. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int 2018;2018:5416923.
79. Dawood S, Austin L, Cristofanilli M. Cancer stem cells: implications for cancer therapy. Oncology 2014;28:1101.
82. Nassar D, Blanpain C. Cancer stem cells: basic concepts and therapeutic implications. Annu Rev Pathol 2016;11:47-76.
83. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010;120:41-50.
84. Poggi A, Varesano S, Zocchi MR. How to hit mesenchymal stromal cells and make the tumor microenvironment immunostimulant rather than immunosuppressive. Front Immunol 2018;9:262.
85. Ishiguro T, Ohata H, Sato A, Yamawaki K, Enomoto T, et al. Tumor-derived spheroids: Relevance to cancer stem cells and clinical applications. Cancer Sci 2017;108:283-9.
86. Yoshida GJ, Saya H. Therapeutic strategies targeting cancer stem cells. Cancer Sci 2016;107:5-11.
88. Newton TC, Wolcott K, Roberts SS. Comparison of the side populations in pretreatment and postrelapse neuroblastoma cell lines. Transl Oncol 2010;3:246-51.
89. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, et al. A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 2004;101:14228-33.
90. Islam MO, Kanemura Y, Tajria J, Mori H, Kobayashi S, et al. Functional expression of ABCG2 transporter in human neural stem/progenitor cells. Neurosci Res 2005;52:75-82.
92. Xing LL, Sha YL, Wu YM, Hu JM, Zhang M, et al. Preliminary analysis of stem cell-like cells in human neuroblastoma. World J Pediatr 2015;11:54-60.
93. Shohet JM, Ghosh R, Coarfa C, Ludwig A, Benham AL, et al. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma. Cancer Res 2011;71:3841-51.
94. Cournoyer S, Nyalendo C, Addioui A, Belounis A, Beaunoyer M, et al. Genotype analysis of tumor-initiating cells expressing CD133 in neuroblastoma. Genes Chromosomes Cancer 2012;51:792-804.
95. Tong QS, Zheng LD, Tang ST, Ruan QL, Liu Y, et al. Expression and clinical significance of stem cell marker CD133 in human neuroblastoma. World J Pediatr 2008;4:58-62.
96. Sartelet H, Imbriglio T, Nyalendo C, Haddad E, Annabi B, et al. CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway. Histopathology 2012;60:1144-55.
97. Takenobu H, Shimozato O, Nakamura T, Ochiai H, Yamaguchi Y, et al. CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene 2011;30:97-105.
98. Khalil MA, Hrabeta J, Groh T, Prochazka P, Doktorova H, et al. Valproic acid increases CD133 positive cells that show low sensitivity to cytostatics in neuroblastoma. PLoS One 2016;11:e0162916.
99. Vangipuram SD, Wang ZJ, Lyman WD. Resistance of stem-like cells from neuroblastoma cell lines to commonly used chemotherapeutic agents. Pediatr Blood Cancer 2010;54:361-8.
100. Ohmichi M, Hayakawa J, Tasaka K, Kurachi H, Murata Y. Mechanisms of platinum drug resistance. Trends Pharmacol Sci 2005;26:113-6.
101. Cipro S, Hrebackova J, Hrabeta J, Poljakova J, Eckschlager T. Valproic acid overcomes hypoxia-induced resistance to apoptosis. Oncol Rep 2012;27:1219-26.
102. Cantilena S, Pastorino F, Pezzolo A, Chayka O, Pistoia V, et al. Frizzled receptor 6 marks rare, highly tumourigenic stem-like cells in mouse and human neuroblastomas. Oncotarget 2011;2:976-83.
103. Vieira GC, Chockalingam S, Melegh Z, Greenhough A, Malik S, et al. LGR5 regulates pro-survival MEK/ERK and proliferative Wnt/beta-catenin signalling in neuroblastoma. Oncotarget 2015;6:40053-67.
104. Forgham H, Johnson D, Carter N, Veuger S, Carr-Wilkinson J. Stem cell markers in neuroblastoma - an emerging role for LGR5. Front Cell Dev Biol 2015;3:77.
105. Marcato P, Dean CA, Giacomantonio CA, Lee PW. Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle 2011;10:1378-84.
106. Hartomo TB, Van Huyen Pham T, Yamamoto N, Hirase S, Hasegawa D, et al. Involvement of aldehyde dehydrogenase 1A2 in the regulation of cancer stem cell properties in neuroblastoma. Int J Oncol 2015;46:1089-98.
107. Flahaut M, Jauquier N, Chevalier N, Nardou K, Balmas Bourloud K, et al. Aldehyde dehydrogenase activity plays a key role in the aggressive phenotype of neuroblastoma. BMC Cancer 2016;16:781.
108. Kuo YT, Liu YL, Adebayo BO, Shih PH, Lee WH, et al. JARID1B expression plays a critical role in chemoresistance and stem cell-like phenotype of neuroblastoma cells. PLoS One 2015;10:e0125343.
109. Hsu DM, Agarwal S, Benham A, Coarfa C, Trahan DN, et al. G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic. Cancer Res 2013;73:4134-46.
110. Agarwal S, Lakoma A, Chen Z, Hicks J, Metelitsa LS, et al. G-CSF promotes neuroblastoma tumorigenicity and metastasis via STAT3-dependent cancer stem cell activation. Cancer Res 2015;75:2566-79.
111. Baggiolini A, Varum S, Mateos JM, Bettosini D, John N, et al. Premigratory and migratory neural crest cells are multipotent in vivo. Cell Stem Cell 2015;16:314-22.
112. Kirsch F, Kruger C, Schneider A. The receptor for granulocyte-colony stimulating factor (G-CSF) is expressed in radial glia during development of the nervous system. BMC Dev Biol 2008;8:32.
113. Schneider A, Kruger C, Steigleder T, Weber D, Pitzer C, et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 2005;115:2083-98.
114. Chikaraishi K, Takenobu H, Sugino RP, Mukae K, Akter J, et al. CFC1 is a cancer stemness-regulating factor in neuroblastoma. Oncotarget 2017;8:45046-59.
115. Cui H, Hu B, Li T, Ma J, Alam G, et al. Bmi-1 is essential for the tumorigenicity of neuroblastoma cells. Am J Pathol 2007;170:1370-8.
116. Cui H, Ma J, Ding J, Li T, Alam G, et al. Bmi-1 regulates the differentiation and clonogenic self-renewal of I-type neuroblastoma cells in a concentration-dependent manner. J Biol Chem 2006;281:34696-704.
117. Nowak K, Kerl K, Fehr D, Kramps C, Gessner C, et al. BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res 2006;34:1745-54.
119. Ochiai H, Takenobu H, Nakagawa A, Yamaguchi Y, Kimura M, et al. Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma. Oncogene 2010;29:2681-90.
120. Mao L, Ding J, Perdue A, Yang L, Zha Y, et al. Cyclin E1 is a common target of BMI1 and MYCN and a prognostic marker for neuroblastoma progression. Oncogene 2012;31:3785-95.
121. Melone MA, Giuliano M, Squillaro T, Alessio N, Casale F, et al. Genes involved in regulation of stem cell properties: studies on their expression in a small cohort of neuroblastoma patients. Cancer Biol Ther 2009;8:1300-6.
122. Chen D, Wu M, Li Y, Chang I, Yuan Q, et al. Targeting BMI1+ cancer stem cells overcomes chemoresistance and inhibits metastases in squamous cell carcinoma. Cell Stem Cell 2017;20:621-34.
123. Ren H, Du P, Ge Z, Jin Y, Ding D, et al. TWIST1 and BMI1 in cancer metastasis and chemoresistance. J Cancer 2016;7:1074-80.
124. Yin T, Zhang Z, Cao B, Duan Q, Shi P, et al. Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine. Oncotarget 2016;7:37192-204.
125. Siddique HR, Saleem M. Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences. Stem Cells 2012;30:372-8.
126. Yang XX, Ma M, Sang MX, Zhang XY, Liu ZK, et al. BMI-1 suppression increases the radiosensitivity of oesophageal carcinoma via the PI3K/Akt signaling pathway. Oncol Rep 2018;39:667-78.
127. Yan Y, Wang Y, Zhao P, Ma W, Hu Z, et al. BMI-1 promotes self-renewal of radio- and temozolomide (TMZ)-resistant breast cancer cells. Reprod Sci 2017;24:1620-9.
128. Facchino S, Abdouh M, Chatoo W, Bernier G. BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. J Neurosci 2010;30:10096-111.
129. Jandial R, Waters DJ, Chen MY. Cancer stem cells can arise from differentiated neoplastic cells. Neurosurgery 2011;69:N22.
130. Friedmann-Morvinski D, Bushong EA, Ke E, Soda Y, Marumoto T, et al. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 2012;338:1080-4.
131. Nishi M, Sakai Y, Akutsu H, Nagashima Y, Quinn G, et al. Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors. Oncogene 2014;33:643-52.
132. Scaffidi P, Misteli T. In vitro generation of human cells with cancer stem cell properties. Nat Cell Biol 2011;13:1051-61.
133. Vares G, Cui X, Wang B, Nakajima T, Nenoi M. Generation of breast cancer stem cells by steroid hormones in irradiated human mammary cell lines. PLoS One 2013;8:e77124.
134. Kang SK, Park JB, Cha SH. Multipotent, dedifferentiated cancer stem-like cells from brain gliomas. Stem Cells Dev 2006;15:423-35.
135. Oshima N, Yamada Y, Nagayama S, Kawada K, Hasegawa S, et al. Induction of cancer stem cell properties in colon cancer cells by defined factors. PLoS One 2014;9:e101735.
136. Shi L, Fei X, Sun G, Wang Z, Wan Y, et al. Hypothermia stimulates glioma stem spheres to spontaneously dedifferentiate adjacent non-stem glioma cells. Cell Mol Neurobiol 2015;35:217-30.
137. Jeon HM, Jin X, Lee JS, Oh SY, Sohn YW, et al. Inhibitor of differentiation 4 drives brain tumor-initiating cell genesis through cyclin E and notch signaling. Genes Dev 2008;22:2028-33.
138. Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A 2011;108:1397-402.
139. Ikegaki N, Shimada H, Fox AM, Regan PL, Jacobs JR, et al. Transient treatment with epigenetic modifiers yields stable neuroblastoma stem cells resembling aggressive large-cell neuroblastomas. Proc Natl Acad Sci U S A 2013;110:6097-102.
140. Colak S, Medema JP. Cancer stem cells - important players in tumor therapy resistance. FEBS J 2014;281:4779-91.
141. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, et al. Identification of cells initiating human melanomas. Nature 2008;451:345-9.
142. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008;10:R25.
143. Hashimoto N, Tsunedomi R, Yoshimura K, Watanabe Y, Hazama S, et al. Cancer stem-like sphere cells induced from de-differentiated hepatocellular carcinoma-derived cell lines possess the resistance to anti-cancer drugs. BMC Cancer 2014;14:722.
144. Chen X, Liao R, Li D, Sun J. Induced cancer stem cells generated by radiochemotherapy and their therapeutic implications. Oncotarget 2017;8:17301-12.
145. Seo Y, Kim YS, Lee KE, Park TH, Kim Y. Anti-cancer stemness and anti-invasive activity of bitter taste receptors, TAS2R8 and TAS2R10, in human neuroblastoma cells. PLoS One 2017;12:e0176851.
146. Farace C, Oliver JA, Melguizo C, Alvarez P, Bandiera P, et al. Microenvironmental modulation of decorin and lumican in temozolomide-resistant glioblastoma and neuroblastoma cancer stem-like cells. PLoS One 2015;10:e0134111.
147. Diaz-Carballo D, Acikelli AH, Bardenheuer W, Gustmann S, Malak S, et al. Identification of compounds that selectively target highly chemotherapy refractory neuroblastoma cancer stem cells. Int J Clin Pharmacol Ther 2014;52:787-801.
148. Prokocimer M, Davidovich M, Nissim-Rafinia M, Wiesel-Motiuk N, Bar DZ, et al. Nuclear lamins: key regulators of nuclear structure and activities. J Cell Mol Med 2009;13:1059-85.
149. Wu Z, Wu L, Weng D, Xu D, Geng J, et al. Reduced expression of lamin A/C correlates with poor histological differentiation and prognosis in primary gastric carcinoma. J Exp Clin Cancer Res 2009;28:8.
150. Nardella M, Guglielmi L, Musa C, Iannetti I, Maresca G, et al. Down-regulation of the Lamin A/C in neuroblastoma triggers the expansion of tumor initiating cells. Oncotarget 2015;6:32821-40.
151. Kamachi Y, Uchikawa M, Kondoh H. Pairing SOX off: with partners in the regulation of embryonic development. Trends Genet 2000;16:182-7.
152. Fang X, Yu W, Li L, Shao J, Zhao N, et al. ChIP-seq and functional analysis of the SOX2 gene in colorectal cancers. OMICS 2010;14:369-84.
153. Gen Y, Yasui K, Zen Y, Zen K, Dohi O, et al. SOX2 identified as a target gene for the amplification at 3q26 that is frequently detected in esophageal squamous cell carcinoma. Cancer Genet Cytogenet 2010;202:82-93.
154. Ji J, Zheng PS. Expression of Sox2 in human cervical carcinogenesis. Hum Pathol 2010;41:1438-47.
155. Nakatsugawa M, Takahashi A, Hirohashi Y, Torigoe T, Inoda S, et al. SOX2 is overexpressed in stem-like cells of human lung adenocarcinoma and augments the tumorigenicity. Lab Invest 2011;91:1796-804.
156. Xiang R, Liao D, Cheng T, Zhou H, Shi Q, et al. Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer. Br J Cancer 2011;104:1410-7.
157. Yang S, Zheng J, Ma Y, Zhu H, Xu T, et al. Oct4 and Sox2 are overexpressed in human neuroblastoma and inhibited by chemotherapy. Oncol Rep 2012;28:186-92.
158. Yang S, Zheng J, Xiao X, Xu T, Tang W, et al. SOX2 promotes tumorigenicity and inhibits the differentiation of I-type neuroblastoma cells. Int J Oncol 2015;46:317-23.
159. Shi Y, Chichung Lie D, Taupin P, Nakashima K, Ray J, et al. Expression and function of orphan nuclear receptor TLX in adult neural stem cells. Nature 2004;427:78-83.
160. Chavali PL, Saini RK, Zhai Q, Vizlin-Hodzic D, Venkatabalasubramanian S, et al. TLX activates MMP-2, promotes self-renewal of tumor spheres in neuroblastoma and correlates with poor patient survival. Cell Death Dis 2014;5:e1502.
161. Fuchs E, Tumbar T, Guasch G. Socializing with the neighbors: stem cells and their niche. Cell 2004;116:769-78.
162. Ye J, Wu D, Wu P, Chen Z, Huang J. The cancer stem cell niche: cross talk between cancer stem cells and their microenvironment. Tumour Biol 2014;35:3945-51.
163. Jögi A, Øra I, Nilsson H, Lindeheim A, Makino Y, et al. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci U S A 2002;99:7021-6.
164. Holmquist-Mengelbier L, Fredlund E, Lofstedt T, Noguera R, Navarro S, et al. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 2006;10:413-23.
165. Asgharzadeh S, Salo JA, Ji L, Oberthuer A, Fischer M, et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol 2012;30:3525-32.
166. Borriello L, Nakata R, Sheard MA, Fernandez GE, Sposto R, et al. Cancer-associated fibroblasts share characteristics and protumorigenic activity with mesenchymal stromal cells. Cancer Res 2017;77:5142-57.
167. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90:5002-12.
168. Hämmerle B, Yañez Y, Palanca S, Cañete A, Burks DJ, et al. Targeting neuroblastoma stem cells with retinoic acid and proteasome inhibitor. PLoS One 2013;8:e76761.
169. Smith KM, Datti A, Fujitani M, Grinshtein N, Zhang L, et al. Selective targeting of neuroblastoma tumour-initiating cells by compounds identified in stem cell-based small molecule screens. EMBO Mol Med 2010;2:371-84.
170. Bahmad HF, Mouhieddine TH, Chalhoub RM, Assi S, Araji T, et al. The Akt/mTOR pathway in cancer stem/progenitor cells is a potential therapeutic target for glioblastoma and neuroblastoma. Oncotarget 2018;9:33549-61.
171. Castelo-Branco P, Zhang C, Lipman T, Fujitani M, Hansford L, et al. Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition. Clin Cancer Res 2011;17:111-21.
172. Zheng X, Naiditch J, Czurylo M, Jie C, Lautz T, et al. Differential effect of long-term drug selection with doxorubicin and vorinostat on neuroblastoma cells with cancer stem cell characteristics. Cell Death Dis 2013;4:e740.
173. Zaatiti H, Abdallah J, Nasr Z, Khazen G, Sandler A, et al. Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration. Int J Oncol 2018;52:787-803.
174. Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, et al. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res 2008;68:6043-8.
175. Hong H, Stastny M, Brown C, Chang WC, Ostberg JR, et al. Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes. J Immunother 2014;37:93-104.
176. Kunkele A, Taraseviciute A, Finn LS, Johnson AJ, Berger C, et al. Preclinical assessment of CD171-directed CAR T-cell adoptive therapy for childhood neuroblastoma: CE7 epitope target safety and product manufacturing feasibility. Clin Cancer Res 2017;23:466-77.
177. Grinshtein N, Datti A, Fujitani M, Uehling D, Prakesch M, et al. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Cancer Res 2011;71:1385-95.
178. Pajtler KW, Sadowski N, Ackermann S, Althoff K, Schönbeck K, et al. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models. Oncotarget 2017;8:6730-41.
179. Naveen CR, Gaikwad S, Agrawal-Rajput R. Berberine induces neuronal differentiation through inhibition of cancer stemness and epithelial-mesenchymal transition in neuroblastoma cells. Phytomedicine 2016;23:736-44.
180. Kim DW, Ahan SH, Kim TY. Enhancement of arsenic trioxide [As(2)O(3)]-mediated apoptosis using berberine in human neuroblastoma SH-SY5Y cells. J Korean Neurosurg Soc 2007;42:392-9.
181. Choi MS, Yuk DY, Oh JH, Jung HY, Han SB, et al. Berberine inhibits human neuroblastoma cell growth through induction of p53-dependent apoptosis. Anticancer Res 2008;28:3777-84.
182. Li J, Gu L, Zhang H, Liu T, Tian D, et al. Berberine represses DAXX gene transcription and induces cancer cell apoptosis. Lab Invest 2013;93:354-64.
183. Tian X, Hou W, Bai S, Fan J, Tong H, et al. XAV939 inhibits the stemness and migration of neuroblastoma cancer stem cells via repression of tankyrase 1. Int J Oncol 2014;45:121-8.
184. Schiapparelli P, Shahi MH, Enguita-Germán M, Johnsen JI, Kogner P, et al. Inhibition of the sonic hedgehog pathway by cyplopamine reduces the CD133+/CD15+ cell compartment and the in vitro tumorigenic capability of neuroblastoma cells. Cancer Lett 2011;310:222-31.
185. Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 2010;62:919-30.
186. Gheeya JS, Chen QR, Benjamin CD, Cheuk AT, Tsang P, et al. Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma. Cancer Biol Ther 2009;8:2386-95.
187. Prasad R, Katiyar SK. Honokiol, an active compound of magnolia plant, inhibits growth, and progression of cancers of different organs. Adv Exp Med Biol 2016;928:245-65.
188. Marcucci F, Rumio C, Lefoulon F. Anti-cancer stem-like cell compounds in clinical development - an overview and critical appraisal. Front Oncol 2016;6:115.
189. Mishra R, Kaur G. Tinospora cordifolia induces differentiation and senescence pathways in neuroblastoma cells. Mol Neurobiol 2015;52:719-33.
190. Pozzoli G, Petrucci G, Navarra P, Marei HE, Cenciarelli C. Aspirin inhibits proliferation and promotes differentiation of neuroblastoma cells via p21(Waf1) protein up-regulation and Rb1 pathway modulation. J Cell Mol Med 2019;23:7078-87.
191. Farabegoli F, Govoni M, Spisni E, Papi A. Epigallocatechin-3-gallate and 6-OH-11-O-Hydroxyphenanthrene limit BE(2)-C neuroblastoma cell growth and neurosphere formation in vitro. Nutrients 2018;10:1141.
192. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med 1999;341:1165-73.
193. Frappaz D, Michon J, Coze C, Berger C, Plouvier E, et al. LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. J Clin Oncol 2000;18:468-76.
194. George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol 2006;24:2891-6.
195. Kletzel M, Katzenstein HM, Haut PR, Yu AL, Morgan E, et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol 2002;20:2284-92.
196. Moss TJ, Cairo M, Santana VM, Weinthal J, Hurvitz C, et al. Clonogenicity of circulating neuroblastoma cells: implications regarding peripheral blood stem cell transplantation. Blood 1994;83:3085-9.
197. Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994;84:380-3.
198. Yalcin B, Kremer LC, van Dalen EC. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database Syst Rev 2013:CD006301.
199. Kaffenberger J, Basak SA, Ioffreda M. Autologous graft-versus-host disease in a child with stage IV neuroblastoma. Pediatr Dermatol 2015;32:276-9.
200. Grupp SA, Asgharzadeh S, Yanik GA. Neuroblastoma: issues in transplantation. Biol Blood Marrow Transplant 2012;18:S92-100.
201. Fish JD, Grupp SA. Stem cell transplantation for neuroblastoma. Bone Marrow Transplant 2008;41:159-65.
